90673-35-1

Usage

Uses

Used in Chemical Synthesis:
3,8-Diazabicyclo[3.2.1]octane dihydrochloride is used as a catalyst and base in various chemical reactions for its ability to accelerate the reaction process and improve the yield of desired products.
Used in Polyurethane Production:
3,8-Diazabicyclo[3.2.1]octane dihydrochloride is used as a catalyst in the production of polyurethane foams and elastomers, contributing to the formation of these versatile materials with diverse applications in industries such as furniture, automotive, and construction.
Used in Pharmaceutical and Agrochemical Synthesis:
3,8-Diazabicyclo[3.2.1]octane dihydrochloride is used as a catalyst in the synthesis of pharmaceuticals and agrochemicals, enabling the production of various drugs and pesticides that are essential for healthcare and agriculture.
Used in Coatings, Adhesives, and Sealants:
3,8-Diazabicyclo[3.2.1]octane dihydrochloride is used in the formulation of coatings, adhesives, and sealants, enhancing their performance and durability in various applications.
Used as a Pharmaceutical Stabilizer:
3,8-Diazabicyclo[3.2.1]octane dihydrochloride is used as a stabilizer for pharmaceutical formulations, ensuring the stability and efficacy of drugs during storage and use.
Used in Medical Research:
3,8-Diazabicyclo[3.2.1]octane dihydrochloride has shown potential as an anti-HIV agent in medical research, indicating its potential use in the development of treatments for HIV and related conditions.

Upstream product

• 67571-90-8 3-benzyl-3,8-diazabicyclo[3.2.1]octane 
• 201162-53-0 tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate 
• 96483-83-9 3-benzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione 

Downstream Products

• 868406-88-6 3-(5-chloro-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-trifluoromethoxy-phenyl)-1,1-dimethylsulfonyl-urea 
• 868407-05-0 1-(5-chloro-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-methyl-phenyl)-tert-butylsulfonyl-urea 
• 868406-79-5 (5-chloro-4-ethoxy-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-phenyl)-urea 
• 868406-70-6 N-[5-chloro-2-{(E)-3-[3-(4-fluoro-benzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-(1-hydroxy-1-methyl-ethyl)-phenyl]acetamide 
• 868406-56-8 1-(5-chloro-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-methoxyphenyl)-3-methylurea 
• 868406-78-4 N-(5-chloro-4-ethoxy-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-phenyl)-methanesulfonamide 
• 868406-93-3 (E)-(5-chloro-2-{3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-methylphenyl)-urea 
• 868406-65-9 5-chloro-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-propenyl}-4-methoxy-N,N-dimethyl-benzenesulfonamide 
• 868406-75-1 N-(5-chloro-4-ethoxy-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-phenyl)-acetamide 
• 868406-59-1 (E)-(5-chloro-2-{3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-methoxyphenyl)-urea 
• 868406-31-9 (E)-(5-chloro-2-{3-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl}phenyl)-carbamic acid tert-butyl ester 
• 868407-12-9 N-(4-bromo-5-chloro-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-phenyl)-acetamide 
• 868408-80-4 N-(5-chloro-4-fluoro-2-{(E)-3-[3-(4-fluoro-benzyl)-3,8-diaza-bicyclo[3.2.1]oct-8-yl]-3-oxo-propenyl}-phenyl)-acetamide 
• 868406-52-4 (E)-(5-chloro-2-{3-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl}-phenyl)-urea 

Relevant academic research and scientific papers

THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I): (I) and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.

Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine

A series of novel N3/8-disubstituted-3,8-diazabicyclo[3.2.1]octanes in order to improve the in vitro activity of the prototype 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridyl-4-yl)methylpiperazine (1) were synthesized and evaluated by assays of growth inhibition against several tumor cell lines. Compounds 2a,b,f and m demonstrated not only growth-inhibitory activities against leukemia cancer cells, but also fairly good activities against the growth of certain solid tumors. Among them, 2a is the most potent one with IC50 values in the low micromolar range. Moreover, compound 2a has been selected for in vitro testing on MCF-7 cell to evaluate the mode of action of this lead compound.